100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
284462-37-9Sorafenib Aminophenoxy Impurity
● In Stock
| Catalogue No.: | VE005959 |
|---|---|
| CAS No.: | 284462-37-9 |
| Mol. Formula: | C13H13N3O2 |
| Mol. Weight: | 243.26 g/mol |
Additional information on CAS 284462-37-9
Parent drug
SorafenibIUPAC Name
4-(4-Aminophenoxy)-N-methylpyridine-2-carboxamidePharmacopeial Synonyms
Sorafenib EP Impurity A; Sorafenib Impurity ASynonyms
4-(4-Aminophenoxy)-N-methylpicolinamide; 2-Pyridinecarboxamide, 4-(4-aminophenoxy)-N-methyl-Smiles
O=C(NC)C1=NC=CC(OC2=CC=C(N)C=C2)=C1InChI
InChI=1S/C13H13N3O2/c1-15-13(17)12-8-11(6-7-16-12)18-10-4-2-9(14)3-5-10/h2-8H,14H2,1H3,(H,15,17)Description
Sorafenib Aminophenoxy Impurity, also designated Sorafenib EP Impurity A and Sorafenib Impurity A, CAS 284462-37-9, is the aniline-linked precursor 4-(4-aminophenoxy)-N-methylpicolinamide, formula C13H13N3O2, molecular weight 243.26 g/mol. Structurally it corresponds to an aryl ether intermediate associated with sorafenib synthesis, commonly arising from incomplete coupling or insufficient amination during route development. It is not a nitrosamine, but its presence is controlled as a process-related related substance under pharmacopoeial impurity profiling. Determination typically requires LC-MS/MS or high-resolution LC-MS, with orthogonal confirmation by HPLC-UV and, when needed, NMR characterization.References
Johnsirani, P., et al. “LC-ESI-QTOF-MS Analysis Utilizing Gas-Phase Fragmentation Reactions Subjected to ESI-IS-CID and ESI-CID-MS/MS Conditions to Study the Degradation Behaviour of Sorafenib Tosylate: NMR and in Vitro Cytotoxicity and Apoptosis Detection Studies of Hydrolytic Degradation Products.” Journal of Pharmaceutical and Biomedical Analysis, vol. 177, Jan. 2020, p. 112881, https://doi.org/10.1016/j.jpba.2019.112881. ?Request a Quote
"*" indicates required fields
Other products related to Sorafenib impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
